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Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry was used to study
peptide–peptide interaction. The interaction was seen when 6-aza-2-thiothymine was used as
a matrix (pH 5.4), but was disrupted with a more acidic matrix, a-cyano-4-hydroxycinnamic
acid (pH 2.0). In the present study, we show that dynorphin, an opioid peptide, and five of its
fragments that contain two adjacent basic residues (Arg6-Arg7), all interact noncovalently with
peptides that contain two to five adjacent acidic residues (Asp or Glu). Two other nonrelated
peptides containing two (Arg6-Arg7) or three (Arg1-Lys2-Arg3) adjacent basic amino acid
residues were studied and exhibited the same behavior. However, peptides containing
adjacent Lys or His did not form noncovalent complexes with acidic peptides. The noncovalent
bonding was sufficiently stable that digestion with trypsin only cleaved Arg and Lys residues
that were not involved in hydrogen bonding with the acidic residues. In an equimolar mixture
of dynorphin, dynorphin fragments (containing the motif RR), and an acidic peptide
(minigastrin), the acidic peptide preferentially complexed with dynorphin. If the concentration
of minigastrin was increased 10 fold, noncovalent interaction was seen with dynorphin and all
its fragments containing the motif RR. In the absence of dynorphin, minigastrin formed
noncovalent complexes with all dynorphin fragments. These findings suggest that conforma-
tion, equilibrium, and concentration do play a role in the occurrence of peptide–peptide
interaction. Observations from this study include: (1) ionic bonds were not disrupted by
enzymatic digests, (2) conformation and concentration influenced complex formation, and (3)
the complex did not form with fragments of dynorphin or unrelated peptides that did not
contain the motifs RR or RKR, nor with a fragment of dynorphin where Arg7 was mutated to
a phenylalanine residue. These findings strongly suggest that peptide–peptide interaction does
occur, and can be studied by MALDI if near physiologic pH is maintained. (J Am Soc Mass
Spectrom 2001, 12, 88–96) © 2001 American Society for Mass Spectrometry
Mass spectrometry is becoming the tool ofchoice to study biopolymers. Ganem et al.[1, 2] were the first to demonstrate that non-
covalent compounds could be studied by electrospray
ionization (ESI) mass spectrometry and Loo wrote an
extensive review on the subject [3]. Although ESI is
considered to be the method of choice for studying
noncovalent interaction, matrix-assisted laser desorp-
tion/ionization (MALDI) provides an alternative sim-
pler approach. In 1995, Woods et al. [4] showed that
noncovalent interaction (zinc finger, enzyme–substrate
complexes) could be studied by MALDI if matrix and
sample conditions were optimized to prevent hydrogen
bonding disruption. Several laboratories have used
MALDI to observe noncovalent interaction. Lecchi and
Pannell [5] showed that a less acidic matrix [6-aza-2-
thiothymine (ATT)] in the presence of ammonium ci-
trate allowed the detection of intact double stranded
DNA. Biemann’s and Vertes’ groups [6, 7] demon-
strated the attachment between highly acidic DNA
strands and basic peptides. Farmer and Caprioli also
studied protein–protein and peptide–protein interac-
tion, as well as publishing an excellent review on the
subject [8]. Hillenkemp’s group claimed that noncova-
lent interaction can only be seen by MALDI if you
gather first shots of crystals that have not been previ-
ously irradiated [9]. Further work by Lin, Cotter, and
Woods detected noncovalent interaction of single and
double stranded DNA with peptides [10, 11].
The purpose of this study is to explore the interaction
between basic peptides, such as dynorphin and its
fragments [12], and acidic peptides such as minigastrin
[13], and to identify the structural elements that drive
the interaction. Dynorphin and its fragments are of
great interest as they are alleged to act at aspartate and
glutamate receptors in the nervous system [14]. We
describe the conditions that govern the formation of
noncovalent complexes between peptides. Another of
our goals is to set up new techniques that can facilitate
the study of such complexes. We will discuss the
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stability of the interaction, and the use of peptide foot-
printing to determine the site of interaction, as well as
the role conformation and equilibrium play in such
interaction. We will also show the crucial role of sample
preparation, specifically matrix pH, plays in conserving
ionic bonding and allowing detection by MALDI.
Materials and Methods
(a) Peptides: Dynorphin (D), dynorphin 1–7 (DF 1–7),
dynorphin 1–8 (DF 1–8), dynorphin 1–9 (DF 1–9),
dynorphin 1–10 (DF 1–10), dynorphin 1–13 (DF 1–13),
minigastrin (MG), and basic peptides 1, 2, 3, 4, and 5 (BP
1, BP 2, BP 3, BP 4, BP 5) were purchased from Sigma
(St. Louis, MO), dynorphin fragment 8–17 (DF 8–17)
and [phe7]dynorphin 1–7 (DF [phe7] 1–7) from Ameri-
can Peptide (Sunnyvale, CA) and acidic peptides 1, 2, 3,
and 4 (AP1, AP2, AP3, AP4) were synthesized by the
core facility of the Biological Chemistry department at
the Johns Hopkins School of Medicine. All peptides
were dissolved in milli-Q water to a concentration of 10
pmol/mL (Table 1). The dynorphin–acidic peptide mix-
tures were made by adding equal amounts of the
working solutions of each of the following to an acidic
peptide: dynorphin, dynorphin 1–7, dynorphin 1–8,
dynorphin 1–9, dynorphin 1–10, and dynorphin 1–13.
Another mixture containing dynorphin and its frag-
ments (the concentration of each of the components was
1 pmol/mL) and minigastrin (10 pmol/mL).
(b) Enzyme: Sequencing grade, modified trypsin,
which cleaves at the carboxyl terminus of both Arg and
Lys, was purchased from Roche Molecular Biochemi-
cals (Indianapolis, IN). The enzyme was diluted to a
concentration of 0.01 mg/mL, so that very short incuba-
tion times could be used.
(c) Matrix: 6-aza-2-thiothymine (ATT) and a-cyano-
4-hydroxycinnamic acid (CHCA) were purchased from
Aldrich (Milwaukee, WI). All matrices were prepared
fresh daily as a saturated solution in 50% ethanol.
(d) Tryptic digests: Test samples: 2 mL peptide 1 4
mL 25 mM ammonium bicarbonate pH 8.0 1 1 mL 0.01
mg/mL trypsin, 0.3 mL aliquots of the digest were
deposited on the sample plate, and the reaction was
stopped at 1, 3, 5, and 10 min by addition of 0.3 mL
matrix. Blank samples were simultaneously studied,
water was substituted for peptide.
(e) Sample preparation: 0.3 mL peptide 1 0.3 mL
matrix (ATT or CHCA).
(f) Instrument: Mass spectra were acquired in lin-
ear mode in both positive and negative ion mode on a
DE-PRO MALDI from PE-Biosystems (Framingham,
MA), equipped with a nitrogen laser (337 nm) and an




To test if peptide–peptide noncovalent interaction could
be studied by MALDI, mixtures of equal amounts of a
solution of minigastrin LEEEEEAYGWMDF-NH2 and
solutions of various peptides were made. Aliquots (0.3
mL) from each mixture were deposited on the sample
plate, followed by the addition of 0.3 mL of ATT and
spectra were acquired. Only the mixture of minigastrin,
and the two peptides that contained the motifs RKR or
RR formed a complex. No complexes were formed with
peptides containing the motif KK. The positive ion
mode spectrum of the mixture of minigastrin and
RKRLARKE (basic peptide 1) gave three molecular ions
(MH1) at m/z 944.1, 1647.7 (the two peptides), and
Table 1. Peptide list
Sequence MW IPa BBb Name
YGGFLRRIRPKLKWNDQ 2147.5 11.36 21990 dynorphin
YGGFLRRIRPKLK 1604.0 12.16 23260 dynorphin 1–13
YGGFLRRIRP 1234.5 12.16 22530 dynorphin 1–10
YGGFLRRIR 1137.4 12.16 22360 dynorphin 1–9
YGGFLRRI 981.2 11.05 23050 dynorphin 1–8
YGGFLRR 868.2 11.05 21600 dynorphin 1–7
YGGFLRF 859.0 11.05 23810 [phe7]dynorphin 1–7
IRPKLKWNDQ 1297.5 9.99 2390 dynorphin 8–17
RKRARKE 943.1 11.72 4110 basic peptide 1
QRRQRKSRRTI 1484.7 12.60 5110 basic peptide 2
KKGE 460.5 . . . 2240 basic peptide 3
SYSMEHFRWGKPVGKKR 2093.4 10.45 690 basic peptide 4
ADAQHATPPKKKRKVEDPKDF 2406.7 9.40 6330 basic peptide 5
LEEEEEAYGWMDF-NH2 1646.7 2.95 21880 minigastrin
YLRKDDDDDY 1317.3 3.71 2310 acidic peptide 1
GYLRKDDDDY 1259.3 3.86 2110 acidic peptide 2
KGYLRKDDDY 1272.4 7.01 2260 acidic peptide 3
PKGYLRKDDY 1254.4 9.69 21040 acidic peptide 4
aIP: Isoelectric point.
bBB: Bull and Breeze hydrophobicity index [20].
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2590.8, the noncovalent complex (943.1 1 1646.7 1 1)
(data not shown). The negative ion mode spectrum
exhibited the following (M 2 H)2 at m/z 942.2, 1645.7,
and 2588.6 u (data not shown). The positive ion mode
spectrum of the mixture of minigastrin and QRRQRK-
SRRTI also gave three MH1, m/z 1485.7, 1647.7, and
3132.4 (1484.7 1 1646.7 1 1) (data not shown). We then
acquired spectra of both mixtures using CHCA as a
matrix and only detected the MH1 of the free peptides
(data not shown). The absence of peptide complexes
with the CHCA matrix confirms the disruption of
noncovalent peptide complexes in acidic mediums. To
confirm peptide–peptide interaction, between peptides
containing two or more acidic residues (Asp or Glu)
and peptides containing the motif RR, we studied the
behavior and dynamics of a set of solutions of dynor-
phin, a 17 amino acid opioid peptide and solutions of
five dynorphin fragments that contain the motif RR
(residues 6 and 7), dynorphin 1–7, dynorphin 1–8,
dynorphin 1–9, dynorphin 1–10, dynorphin 1–13, and
two dynorphin fragments that do not contain the RR
motif, [phe7]dynorphin 1–7 and dynorphin 8–17 when
mixed with various acidic peptides. Equimolar solu-
tions of minigastrin, dynorphin and minigastrin and
each of the dynorphin fragments were made, and
spectra were acquired using ATT or CHCA for matrix.
When using ATT as matrix, noncovalent complexes
were seen with all fragments except dynorphin 8–17
and [phe7]dynorphin 1–7, which do not contain the RR
motif (Table 2). Equally good spectra were observed in
both positive and negative ion modes, as seen in Figure
1a,b which show the spectra of dynorphin fragment
1–13 and minigastrin mixture. However the positive ion
spectrum shows a higher rate of in source decay of mini-
gastrin when compared to the negative mode spectrum. In
Figure 1a, the b series (from b4 to b12) can be seen in the
lower mass range. The peak at m/z 1788.9 is minigastrin 1
ATT, and the peak at m/z 1745.3 is probably an adduct of
ATT and a fragment of minigastrin that lost CO2. When
CHCA (pH 5 2.0) was used, the noncovalent interaction
was not seen, as no complexes were formed with any
compound due to the electrostatic changes that occur at
acidic pH. Solutions of the four peptides containing 2, 3, 4,
and 5 Asp were made (Table 2 only shows data obtained
with acidic peptides 1 and 2). Equimolar solutions of each
acidic peptide with dynorphin and every dynorphin frag-
ment were made and spectra acquired. Again, when using
ATT, noncovalent complexes with dynorphin and all
dynorphin fragments containing the RR motif (Table 2)
were observed. No complexes were detected when CHCA
was used as a matrix. However if CHCA’s pH was raised
(pH . 3.0) as previously done [4] by addition of ammo-
nium citrate or bicarbonate complexes can be seen (data
not shown).
Equilibrium
To find out if dynorphin and its fragments showed
equal avidity for minigastrin, an equimolar solution of
dynorphin, its fragments containing the RR motif, and
minigastrin was made. The only complex detected was
between dynorphin and minigastrin at m/z 3795.0, al-
though we see the MH1 of each of the dynorphin
fragments (Figure 2a). The preference for dynorphin
demonstrated by acidic peptides could be due to the
tryptophan residue at position 14. Arg and Trp are the
only two residues that are strict proton donors [15].
However, if the concentration of minigastrin in the
mixture was 10 fold relative to dynorphin and its
fragments, then noncovalent complexes of minigastrin
and dynorphin and all its fragments were formed,
despite the fact that the [M 2 H]2 of dynorphin–mini-
gastrin had a high relative intensity (Figure 2b). This
second finding suggests that equilibrium might be
involved. A side effect of the 10 fold increase in mini-
gastrin relative to dynorphin and its fragments was the
formation of a prominent minigastrin dimer at m/z
3293.1 that partially suppressed the dynorphin frag-
ment 1 to 13–minigastrin complex at m/z 3249.3. The
peak is clearly seen if that area of the spectrum is
enlarged (Figure 2b). To test the role of Trp14 or possibly
the dynorphin conformation, we made an equimolar
mixture of minigastrin and the five dynorphin frag-
ments containing the RR motif (the largest is made up
of residues 1–13). In the absence of dynorphin, the
Table 2. MH1 of mixtures of D 1 MG, DF 1 MG, D 1 AP1,




Dynorphin 1 minigastrin Yes
Dynorphin 1–7 1 minigastrin Yes
Dynorphin 1–8 1 minigastrin Yes
Dynorphin 1–9 1 minigastrin Yes
Dynorphin 1–10 1 minigastrin Yes
Dynorphin 1–13 1 minigastrin Yes
Dynorphin 8–17 1 minigastrin No
[Phe7]dynorphin 1–7 1 minigastrin No
Basic peptide 1 1 minigastrin Yes
Basic peptide 2 1 minigastrin Yes
Basic peptide 3 1 minigastrin No
Basic peptide 4 1 minigastrin No
Basic peptide 5 1 minigastrin No
Dynorphin 1 acidic peptide 1 Yes
Dynorphin 1–7 1 acidic peptide 1 Yes
Dynorphin 1–8 1 acidic peptide 1 Yes
Dynorphin 1–9 1 acidic peptide 1 Yes
Dynorphin 1–10 1 acidic peptide 1 Yes
Dynorphin 1–13 1 acidic peptide 1 Yes
Dynorphin 8–17 1 acidic peptide 1 No
[Phe7]dynorphin 1–7 1 acidic peptide 1 No
Dynorphin 1 acidic peptide 2 Yes
Dynorphin 1–7 1 acidic peptide 2 Yes
Dynorphin 1–8 1 acidic peptide 2 Yes
Dynorphin 1–9 1 acidic peptide 2 Yes
Dynorphin 1–10 1 acidic peptide 2 Yes
Dynorphin 1–13 1 acidic peptide 2 Yes
Dynorphin 8–17 1 acidic peptide 2 No
[Phe7]dynorphin 1–7 1 acidic peptide 2 No
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Figure 1. (a) Positive ion mode spectrum of an equimolar mixture of minigastrin (1647.7 u) and
dynorphin fragment 1–13 (1604.7 u). The MH1 of the noncovalent complex is seen at m/z 3251.7. Note
the in source decay of minigastrin. (b) Negative ion mode spectrum of an equimolar mixture of
minigastrin (1645.8 u) and dynorphin fragment 1–13 (1602.9 u). The [M 2 H]2 of the noncovalent
complex is seen at m/z 3249.3.
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Figure 2. (a) Negative ion mode spectrum of an equimolar mixture of minigastrin (1645.7 u) and
dynorphin (2146.2 u) and dynorphin fragments 1–7 (867.4 u), 1–8 (980.9 u), 1–9 (1136.6 u), 1–10 (1233.6
u), and 1–13 (1603.1 u). The only noncovalent complex seen is that of MG 1 D (3792.9 u). (b) Negative
ion mode spectrum of a mixture where the concentration of minigastrin (1646.0 u) is 10 fold that of the
equimolar mixture of dynorphin (2146.4 u) and dynorphin fragments (DF) 1–7 (867.5 u), 1–8 (980.5 u),
1–9 (1137.0 u), 1–10 (1233.5 u), and 1–13 (1602.8 u). When the concentration of MG is raised,
noncovalent complexes are seen with dynorphin and all its fragments. MG 1 D (3793.0 u), MG 1 DF
1–7 (2513.9 u), MG 1 DF 1–8 (2626.9 u), MG 1 DF 1–9 (2783.1 u), MG 1 DF 1–10 (2880.2 u), and
MG 1 DF 1–13 (3249.1 u).
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spectra showed complexes of minigastrin and every one
of the fragments (Figure 3).
Mixtures where the dynorphin fragments were 2, 5,
10, 20, and 50 fold more dilute than minigastrin were
also tested. Complexes were seen in all cases; however,
the intensities of the complexes’ peaks were signifi-
cantly decreased for the 20 and 50 fold dilutions (data
not shown). The avidity demonstrated by dynorphin
could also be due to its secondary structure. Dynorphin is
the only molecule that forms a-helix (59%), b-turns (6%)
and has only 35% random coils, whereas all dynorphin
fragments and minigastrin are made of random coils. The
a-helix structure allows the positively charged residues to
be maximally exposed and situated so as to interact with
other molecules in solution [16]. When minigastrin is
complexed with dynorphin, modeling shows reduction of
its random coils. Also, when charge versus pH is plotted
for dynorphin, a maximal charge of 16 is seen at pH 0–3,
and 14.5 from 3–12 producing an almost horizontal line.
This could be explained by the isoelectric point (IP) of
dynorphin (IP 5 11.4), as the solubility of a peptide in-
creases at pH values that are furthest away from its IP. The
Bull and Breeze (BB) hydrophobicity index [17] seemed to
indicate that the hydrophobicity or hydrophilicity of the
interacting peptides did not play a role in complex forma-
tion, as it did not enhance or detract the process (Table 1).
Basic peptides 1, 2, and 4 are very hydrophilic, whereas
dynorphin and dynorphin fragments show a range of
hydrophobicity from 2110 to 23260.
Peptide Footprinting
A widely used technique to locate promoter sites on
DNA is done by adding RNA–polymerase to DNA and
then digesting the DNA–RNA–polymerase complex
with a deoxyribonuclease. The polymerases remain
bound to the promoters and protect them from diges-
tion. The string of bases that remains intact pinpoints
the interaction site. Hence, the idea of digesting the
peptide complex with trypsin, to see if the residues
involved in the noncovalent interaction would be
shielded from the enzyme’s reach. We first digested the
equimolar mixture of basic peptide 1 and minigastrin.
The positive ion mode spectrum of the 5 min digest
showed complex peaks at m/z 2590.6 (minigastrin 1
RKRARKE 1 H1) and 2333.5 (minigastrin 1
RKRAR 1 H1). The 10 min digest only shows one
complex at m/z 2106.0 (minigastrin 1 RKR 1 H1) (Fig-
ure 4a,b). The minigastrin dynorphin mixture was also
digested with trypsin under the same conditions. The
reaction progressed much faster. A complex of a dynor-
phin fragment and minigastrin was observed as early as
1 and 3 min, at m/z 2515.6 (1646.7 1 868.0 1 1, [mini-
gastrin 1 YGGFLRR 1 H1]). The dynorphin fragment
Figure 3. Negative ion mode spectrum of an equimolar mixture of minigastrin (1645.8 u) and
dynorphin fragments (DF) 1–7 (867.1 u), 1–8 (980.4 u), 1–9 (1136.7 u), 1–10 (1233.8 u), and 1–13 (1603.0
u). In the absence of dynorphin, noncovalent complexes of MG and all DF are formed. MG 1 DF 1–7
(2513.6 u), MG 1 DF 1–8 (2626.2 u), MG 1 DF 1–9 (2782.6 u), MG 1 DF 1–10 (2880.2 u), and MG 1
DF 1–13 (3248.9).
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Figure 4. (a) Positive ion mode spectrum of the 5 min incubation time of a tryptic digest of an
equimolar mixture of minigastrin (1647.9 u) and basic peptide 1 [RKRARKE] (944.0 u). The MH1 at
686.0 u is the tryptic fragment [RKRAR]. The MH1 at 2590.6 u is the noncovalent complex of
minigastrin and basic peptide 1 and the MH1 at 2333.6 u is the noncovalent complex of minigastrin
and the tryptic fragment [RKRAR]. (b) Positive ion mode spectrum of the 10 min incubation time of
a tryptic digest of an equimolar mixture of minigastrin (1647.7 u) and basic peptide 1 [RKRARKE].
The MH1 at 2106.0 u is the noncovalent complex of minigastrin and basic peptide 1 tryptic fragment
[RKR].
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1–7, MH1 869.0 u was the most prominent fragment
obtained from the digest (Figure 5). In both the cases of
basic peptide 1 and dynorphin, the interactions were
not disrupted by trypsin. Cleavage did occur at the Arg
residue at the carboxyl terminus of the basic peptides in
the complex. However, Arg1 and Lys2 in the case of
basic peptide 1, and Arg6 in the case of dynorphin, were
not accessible for cleavage. Dynorphin alone was di-
gested under the same conditions, a peak at m/z 713
(YGGFLR) was seen among the tryptic fragments,
showing that cleavage does occur if the site is not
shielded.
Peptide–peptide interaction could be explained
through the physical and chemical properties of the side
chains of the residues involved. Arg and Trp are the
only residues whose side chain can serve as hydrogen
donors, whereas Asp and Glu can both receive and
donate hydrogen. The carboxyl groups of Glu and Asp
differ marginally in their physical and chemical prop-
erties. The carboxyl groups of Asp and Glu side chains
ionize with intrinsic pKa values of 3.9 and 4.3, respec-
tively; these residues are ionized and very polar under
physiological conditions. The Arg side chain consists of
three nonpolar methylene groups and a strongly basic
d-guanidium group, which is dissociated over the entire
pH range (pKa is 12.0) [15]. It is likely that a proton
from the Arg side chain is sought after by the delocal-
ized lone pair of electrons on the Asp or Glu side chain
carboxyl group.
These salt bridge interactions also consist of some
degree of hydrogen bonding in addition to the electro-
static interaction. To test the possible role of coulombic
repulsion, we synthesized acidic peptides with an Arg
and a Lys residue adjacent to the Asp residues (acidic
peptides 1, 2, 3, and 4). The presence of these residues
did not prevent noncovalent interaction between the
Arg residues on dynorphin and dynorphin fragments
and the Asp residues on AP1, AP2, AP3, and AP4 from
occurring. Thus, we can assume that the ionic bonds
were stable enough to withstand disruption due to
nearby weak coulombic repulsion forces.
Spectra obtained in both positive and negative
modes were basically equally good. However each
mode had its advantage and disadvantage. Positive
mode usually showed minimal adduct formation with
ATT, but more ISD fragmentation. Negative mode on
the other hand showed more adduct formation with
ATT, but less ISD fragmentation. The ISD of peptides
usually increases with laser power. On our DE–Pro
where the maximum laser power is 4600, a laser power
of 2600 was used for most of the samples prepared with
ATT matrix. However if conditions were optimized, a
laser power of 2100 or less could be used resulting in
less saturation and fragmentation of the free peptides.
In conclusion, the chemistry of basic residues such as
arginine, and acidic residues such as aspartic and
glutamic acid, seem to support the likelihood that
electrostatic attraction of salt bridges and hydrogen
Figure 5. Positive ion mode spectrum of the 3 min incubation time of a tryptic digest of an equimolar
mixture of minigastrin (1647.7 u) and dynorphin. The only noncovalent complex seen is that of MG
and the D tryptic fragment 1–7 (869.0). a6, c6, a7, b11, and a13 are D ISD fragments, while C8, Y10, Y11,
and Z12 are MG fragments.
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bonding between residues is at the base of the observed
peptide–peptide interaction. It is obvious that a pH
range close to physiological pH is needed. Our results
seem to indicate that structure plays an important role,
as dynorphin (the only peptide with a-helix structure)
preferentially interacted with minigastrin. The relative
intensity of the complexes varied from as little as 3% to
as much as 70% (data not shown).
However, a 10 fold increase in the concentration of
minigastrin relative to that of dynorphin and its frag-
ments led to complex formation with all the fragments
in addition to dynorphin, probably due to a shift in
complex formation and dissociation. This finding was
further supported by the fact that removal of dynorphin
from the mixture resulted in all its fragments forming
complexes with minigastrin. The dynamics of noncova-
lent complex formation between dynorphin, its fragments,
and minigastrin also suggest that equilibrium may be
involved. The observation of noncovalent complex stabil-
ity was further supported by the “peptide footprinting”
experiment, which demonstrated that the interaction was
stable enough to avoid disruption by enzymatic digestion.
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